Involvement of long noncoding RNAs in diseases affecting the central nervous system

RNA Biology

Volumn 9, Issue 6, 2012, Pages 860-870

  Pastori, Chiara ^a   Wahlestedt, Claes ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Brain cancer; Epigenetics; Long noncoding RNAs; Neurological disorders; RNA binding proteins; RNA targeting therapies

Indexed keywords

LONG UNTRANSLATED RNA; UNCLASSIFIED DRUG; UNTRANSLATED RNA;

ALZHEIMER DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CENTRAL NERVOUS SYSTEM TUMOR; FRAGILE X SYNDROME; GENETIC VARIABILITY; GENOME ANALYSIS; HAPPY PUPPET SYNDROME; HUMAN; HUMAN GENOME; HUNTINGTON CHOREA; NONHUMAN; PROTEIN EXPRESSION; PROTEIN TARGETING; REVIEW; SPINOCEREBELLAR DEGENERATION;

EID: 84863489478     PISSN: 15476286     EISSN: 15558584     Source Type: Journal    
DOI: 10.4161/rna.20482     Document Type: Review

References (136)

1. Seila AC, Calabrese JM, Levine SS, Yeo GW, Rahl PB, Flynn RA, et al. Divergent transcription from active promoters. Science 2008; 322:1849-51; PMID:19056940; http://dx.doi.org/10.1126/science.1162253.
2. Preker P, Nielsen J, Kammler S, Lykke-Andersen S, Christensen MS, Mapendano CK, et al. RNA exosome depletion reveals transcription upstream of active human promoters. Science 2008; 322:1851-4; PMID:19056938; http://dx.doi.org/10.1126/science.1164096.
3. Pandey RR, Mondal T, Mohammad F, Enroth S, Redrup L, Komorowski J, et al. Kcnq1ot1 antisense noncoding RNA mediates lineage-specific transcriptional silencing through chromatin-level regulation. Mol Cell 2008; 32:232-46; PMID:18951091; http://dx.doi.org/10.1016/j.molcel.2008.08.022.
4. Nagano T, Mitchell JA, Sanz LA, Pauler FM, Ferguson-Smith AC, Feil R, et al. The Air noncoding RNA epigenetically silences transcription by targeting G9a to chromatin. Science 2008; 322:1717-20; PMID:18988810; http://dx.doi.org/10. 1126/science.1163802.
5. He Y, Vogelstein B, Velculescu VE, Papadopoulos N, Kinzler KW. The antisense transcriptomes of human cells. Science 2008; 322:1855-7; PMID:19056939; http://dx.doi.org/10.1126/science.1163853.
6. Finocchiaro G, Carro MS, Francois S, Parise P, DiNinni V, Muller H. Localizing hotspots of antisense transcription. Nucleic Acids Res 2007; 35:1488-500; PMID:17284453; http://dx.doi.org/10.1093/nar/gkm027.
7. Core LJ, Lis JT. Transcription regulation through promoter-proximal pausing of RNA polymerase II. Science 2008; 319:1791-2; PMID:18369138; http://dx.doi.org/10.1126/science.1150843.
8. Kapranov P, Cheng J, Dike S, Nix DA, Duttagupta R, Willingham AT, et al. RNA maps reveal new RNA classes and a possible function for pervasive transcription. Science 2007; 316:1484-8; PMID:17510325; http://dx.doi.org/10. 1126/science.1138341.
9. Ladd PD, Smith LE, Rabaia NA, Moore JM, Georges SA, Hansen RS, et al. An antisense transcript spanning the CGG repeat region of FMR1 is upregulated in premutation carriers but silenced in full mutation individuals. Hum Mol Genet 2007; 16:3174-87; PMID:17921506; http://dx.doi.org/10.1093/hmg/ddm293.
10. Khalil AM, Faghihi MA, Modarresi F, Brothers SP, Wahlestedt C. A novel RNA transcript with antiapoptotic function is silenced in fragile X syndrome. PLoS One 2008; 3:1486; PMID:18213394; http://dx.doi.org/10.1371/journal.pone. 0001486.
11. Guttman M, Amit I, Garber M, French C, Lin MF, Feldser D, et al. Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals. Nature 2009; 458:223-7; PMID:19182780; http://dx.doi.org/10. 1038/nature07672.
12. Amaral PP, Clark MB, Gascoigne DK, Dinger ME, Mattick JS. lncRNAdb: a reference database for long noncoding RNAs. Nucleic Acids Res 2011; 39:146-51; PMID:21112873; http://dx.doi.org/10.1093/nar/gkq1138.
13. Munroe SH, Lazar MA. Inhibition of c-erbA mRNA splicing by a naturally occurring antisense RNA. J BiolChem 1991; 266:22083-6; PMID:1657988.
14. Faghihi MA, Modarresi F, Khalil AM, Wood DE, Sahagan BG, Morgan TE, et al. Expression of a non-coding RNA is elevated in Alzheimer's disease and drives rapid feed-forward regulation of beta-secretase. Nat Med 2008; 14:723-30; PMID:18587408; http://dx.doi.org/10.1038/nm1784.
15. Mercer TR, Dinger ME, Mattick JS. Long non-coding RNAs: insights into functions. Nat Rev Genet 2009; 10:155-9; PMID:19188922; http://dx.doi.org/10. 1038/nrg2521.
16. Feng J, Bi C, Clark BS, Mady R, Shah P, Kohtz JD. The Evf-2 noncoding RNA is transcribed from the Dlx-5/6 ultraconserved region and functions as a Dlx-2 transcriptional coactivator. Genes Dev 2006; 20:1470-84; PMID:16705037; http://dx.doi.org/10.1101/gad.1416106.
17. Martianov I, Ramadass A, Serra Barros A, Chow N, Akoulitchev A. Repression of the human dihydrofolatereductase gene by a non-coding interfering transcript. Nature 2007; 445:666-70; PMID:17237763; http://dx.doi.org/10.1038/ nature05519.
18. Wang X, Arai S, Song X, Reichart D, Du K, Pascual G, et al. Induced ncRNAsallosterically modify RNA-binding proteins in cis to inhibit transcription. Nature 2008; 454:126-30; PMID:18509338; http://dx.doi.org/10. 1038/nature06992.
19. Yu W, Gius D, Onyango P, Muldoon-Jacobs K, Karp J, Feinberg AP, et al. Epigenetic silencing of tumour suppressor gene p15 by its antisense RNA. Nature 2008; 451:202-6; PMID:18185590; http://dx.doi.org/10.1038/nature06468.
20. Yap KL, Li S, Muñoz-Cabello AM, Raguz S, Zeng L, Mujtaba S, et al. Molecular interplay of the non-coding RNA ANRIL and methylated histone H3 lysine 27 by polycomb CBX7 in transcriptional silencing of INK4a. Mol Cell 2010; 38:662-74; PMID:20541999; http://dx.doi.org/10.1016/j.molcel.2010.03.021.
21. Morris KV, Santoso S, Turner AM, Pastori C, Hawkins PG. Bidirectional transcription directs both transcriptional gene activation and suppression in human cells. PLoS Genet 2008; 4:1000258; PMID:19008947; http://dx.doi.org/10. 1371/journal.pgen.1000258.
22. Khalil AM, Guttman M, Huarte M, Garber M, Raj A, Rivea Morales D, et al. Many human large intergenic noncoding RNAs associate with chromatin-modifying complexes and affect gene expression. Proc Natl Acad Sci USA 2009; 106:11667-72; PMID:19571010; http://dx.doi.org/10.1073/pnas.0904715106.
23. Rinn JL, Kertesz M, Wang JK, Squazzo SL, Xu X, Brugmann SA, et al. Functional demarcation of active and silent chromatin domains in human HOX loci by noncoding RNAs. Cell 2007; 129:1311-23; PMID:17604720; http://dx.doi.org/10. 1016/j.cell.2007.05.022.
24. Gräff J, Kim D, Dobbin MM, Tsai LH. Epigenetic regulation of gene expression in physiological and pathological brain processes. Physiol Rev 2011; 91:603-49; PMID:21527733; http://dx.doi.org/10.1152/physrev.00012.2010.
25. Mercer TR, Dinger ME, Mariani J, Kosik KS, Mehler MF, Mattick JS. Noncoding RNAs in Long-Term Memory Formation. Neuroscientist 2008; 14:434-45; PMID:18997122; http://dx.doi.org/10.1177/1073858408319187.
26. Bernard D, Prasanth KV, Tripathi V, Colasse S, Nakamura T, Xuan Z, et al. A long nuclear-retained non-coding RNA regulates synaptogenesis by modulating gene expression. EMBO J 2010; 29:3082-93; PMID:20729808; http://dx.doi.org/10. 1038/emboj.2010.199.
27. Pollard KS, Salama SR, Lambert N, Lambot MA, Coppens S, Pedersen JS, et al. An RNA gene expressed during cortical development evolved rapidly in humans. Nature 2006; 443:167-72; PMID:16915236; http://dx.doi.org/10.1038/nature05113.
28. Mehler MF, Mattick JS. Non-coding RNAs in the nervous system. J Physiol 2006; 575:333-41; PMID:16809366; http://dx.doi.org/10.1113/jphysiol.2006.113191.
29. Mercer TR, Qureshi IA, Gokhan S, Dinger ME, Li G, Mattick JS, et al. Long noncoding RNAs in neuronal-glial fate specification and oligodendrocyte lineage maturation. BMC Neurosci 2010; 11:14; PMID:20137068; http://dx.doi.org/10.1186/ 1471-2202-11-14.
30. Qureshi IA, Mattick JS, Mehler MF. Long non-coding RNAs in nervous system function and disease. Brain Res 2010; 1338:20-35; PMID:20380817; http://dx.doi.org/10.1016/j.brainres.2010.03.110.
31. Mehler MF, Mattick JS. Noncoding RNAs and RNA editing in brain development, functional diversification and neurological disease. Physiol Rev 2007; 87:799-823; PMID:17615389; http://dx.doi.org/10.1152/physrev.00036.2006.
32. Mehler MF. Epigenetics and the nervous system. Ann Neurol 2008; 64:602-17; PMID:19107999; http://dx.doi.org/10.1002/ana.21595.
33. Taft RJ, Pang KC, Mercer TR, Dinger M, Mattick JS. Non-coding RNAs: regulators of disease. J Pathol 2010; 220:126-39; PMID:19882673; http://dx.doi.org/10.1002/path.2638.
34. Eacker SM, Dawson TM, Dawson VL. Understanding microRNAs in neurodegeneration. Nat Rev Neurosci 2009; 10:837-41; PMID:19904280; http://dx.doi.org/10.1038/nrn2726.
35. Esteller M. Non-coding RNAs in human disease. Nat Rev Genet 2011; 12:861-74; PMID:22094949; http://dx.doi.org/10.1038/nrg3074.
36. Kosik KS. The neuronal microRNA system. Nat Rev Neurosci 2006; 7:911-20; PMID:17115073; http://dx.doi.org/10.1038/nrn2037.
37. Miller BH, Wahlestedt C. MicroRNA dysregulation in psychiatric disease. Brain Res 2010; 1338:89-99; PMID:20303342; http://dx.doi.org/10.1016/j.brainres. 2010.03.035.
38. López Castel A, Cleary JD, Pearson CE. Repeat instability as the basis for human diseases and as a potential target for therapy. Nat Rev Mol Cell Biol 2010; 11:165-70; PMID:20177394; http://dx.doi.org/10.1038/nrm2854.
39. Mirkin SM. Expandable DNA repeats and human disease. Nature 2007; 447:932-40; PMID:17581576; http://dx.doi.org/10.1038/nature05977.
40. Moseley ML, Zu T, Ikeda Y, Gao W, Mosemiller AK, Daughters RS, et al. Bidirectional expression of CUG and CAG expansion transcripts and intranuclearpolyglutamine inclusions in spinocerebellar ataxia type 8. Nat Genet 2006; 38:758-69; PMID:16804541; http://dx.doi.org/10.1038/ng1827.
41. Cho DH, Thienes CP, Mahoney SE, Analau E, Filippova GN, Tapscott SJ. Antisense transcription and heterochromatin at the DM1 CTG repeats are constrained by CTCF. Mol Cell 2005; 20:483-9; PMID:16285929; http://dx.doi.org/10.1016/j.molcel.2005.09.002.
42. David G, Abbas N, Stevanin G, Dürr A, Yvert G, Cancel G, et al. Cloning of the SCA7 gene reveals a highly unstable CAG repeat expansion. Nat Genet 1997; 17:65-70; PMID:9288099; http://dx.doi.org/10.1038/ng0997-65.
43. Lindblad K, Savontaus ML, Stevanin G, Holmberg M, Digre K, Zander C, et al. An expanded CAG repeat sequence in spinocerebellar ataxia type 7. Genome Res 1996; 6:965-71; PMID:8908515; http://dx.doi.org/10.1101/gr.6.10.965.
44. Sopher BL, Ladd PD, Pineda VV, Libby RT, Sunkin SM, Hurley JB, et al. CTCF regulates ataxin-7 expression through promotion of a convergently transcribed, antisense noncoding RNA. Neuron 2011; 70:1071-84; PMID:21689595; http://dx.doi.org/10.1016/j.neuron.2011.05.027.
45. Barski A, Cuddapah S, Cui K, Roh TY, Schones DE, Wang Z, et al. High-resolution profiling of histone methylations in the human genome. Cell 2007; 129:823-37; PMID:17512414; http://dx.doi.org/10.1016/j.cell.2007.05.009.
46. Filippova GN. Genetics and epigenetics of the multifunctional protein CTCF. Curr Top Dev Biol 2008; 80:337-60; PMID:17950379; http://dx.doi.org/10. 1016/S0070-2153(07)80009-3.
47. Daughters RS, Tuttle DL, Gao W, Ikeda Y, Moseley ML, Ebner TJ, et al. RNA gain-of-function in spinocerebellar ataxia type 8. PLoS Genet 2009; 5:1000600; PMID:19680539; http://dx.doi.org/10.1371/journal.pgen.1000600.
48. Chen IC, Lin HY, Lee GC, Kao SH, Chen CM, Wu YR, et al. Spinocerebellar ataxia type 8 larger triplet expansion alters histone modification and induces RNA foci. BMC Mol Biol 2009; 10:9; PMID:19203395; http://dx.doi.org/10.1186/ 1471-2199-10-9.
49. Pearson CE, Nichol Edamura K, Cleary JD. Repeat instability: mechanisms of dynamic mutations. Nat Rev Genet 2005; 6:729-42; PMID:16205713; http://dx.doi.org/10.1038/nrg1689.
50. Ohlsson R, Renkawitz R, Lobanenkov V. CTCF is a uniquely versatile transcription regulator linked to epigenetics and disease. Trends Genet 2001; 17:520-7; PMID:11525835; http://dx.doi.org/10.1016/S0168-9525(01)02366-6.
51. Batra R, Charizanis K, Swanson MS. Partners in crime: bidirectional transcription in unstable microsatellite disease. Hum Mol Genet 2010; 19:77-82; PMID:20368264; http://dx.doi.org/10.1093/hmg/ddq132.
52. Clark AG, Glanowski S, Nielsen R, Thomas PD, Kejariwal A, Todd MA, et al. Inferring nonneutral evolution from human-chimp-mouse orthologous gene trios. Science 2003; 302:1960-3; PMID:14671302; http://dx.doi.org/10.1126/science. 1088821.
53. Nielsen R. Molecular signatures of natural selection. Annu Rev Genet 2005; 39:197-218; PMID:16285858; http://dx.doi.org/10.1146/annurev.genet.39. 073003.112420.
54. Lander ES. Initial impact of the sequencing of the human genome. Nature 2011; 470:187-97; PMID:21307931; http://dx.doi.org/10.1038/nature09792.
55. Siepel A, Bejerano G, Pedersen JS, Hinrichs AS, Hou M, Rosenbloom K, et al. Evolutionarily conserved elements in vertebrate, insect, worm and yeast genomes. Genome Res 2005; 15:1034-50; PMID:16024819; http://dx.doi.org/10.1101/ gr.3715005.
56. Zuccato C, Cattaneo E. Role of brain-derived neurotrophic factor in Huntington's disease. ProgNeurobiol 2007; 81:294-330; PMID:17379385; http://dx.doi.org/10.1016/j.pneurobio.2007.01.003.
57. Johnson DS, Mortazavi A, Myers RM, Wold B. Genome-wide mapping of in vivo protein-DNA interactions. Science 2007; 316:1497-502; PMID:17540862; http://dx.doi.org/10.1126/science.1141319.
58. Fowden AL, Sibley C, Reik W, Constancia M. Imprinted genes, placental development and fetal growth. Horm Res 2006; 65:50-8; PMID:16612114; http://dx.doi.org/10.1159/000091506.
59. Davies W, Isles AR, Wilkinson LS. Imprinted gene expression in the brain. Neurosci Biobehav Rev 2005; 29:421-30; PMID:15820547; http://dx.doi.org/10. 1016/j.neubiorev.2004.11.007.
60. Wilkinson LS, Davies W, Isles AR. Genomic imprinting effects on brain development and function. Nat Rev Neurosci 2007; 8:832-43; PMID:17925812; http://dx.doi.org/10.1038/nrn2235.
61. Schulze TG, Buervenich S, Badner JA, Steele CJ, Detera-Wadleigh SD, Dick D, et al. Loci on chromosomes 6q and 6p interact to increase susceptibility to bipolar affective disorder in the national institute of mental health genetics initiative pedigrees. Biol Psychiatry 2004; 56:18-23; PMID:15219468; http://dx.doi.org/10.1016/j.biopsych.2004.04.004.
62. Schanen NC. Epigenetics of autism spectrum disorders. Hum Mol Genet 2006; 15:138-50; PMID:16987877; http://dx.doi.org/10.1093/hmg/ddl213.
63. Francks C, DeLisi LE, Shaw SH, Fisher SE, Richardson AJ, Stein JF, et al. Parent-of-origin effects on handedness and schizophrenia susceptibility on chromosome 2p12-q11. Hum Mol Genet 2003; 12:3225-30; PMID:14583442; http://dx.doi.org/10.1093/hmg/ddg362.
64. Katayama S, Tomaru Y, Kasukawa T, Waki K, Nakanishi M, Nakamura M, et al.; RIKEN Genome Exploration Research Group; Genome Science Group (Genome Network Project Core Group); FANTOM Consortium. Antisense transcription in the mammalian transcriptome. Science 2005; 309:1564-6; PMID:16141073; http://dx.doi.org/10.1126/science.1112009.
65. Chamberlain SJ, Lalande M. Angelman syndrome, a genomic imprinting disorder of the brain. J Neurosci 2010; 30:9958-63; PMID:20668179; http://dx.doi.org/10.1523/JNEUROSCI.1728-10.2010.
66. Yamasaki K, Joh K, Ohta T, Masuzaki H, Ishimaru T, Mukai T, et al. Neurons but not glial cells show reciprocal imprinting of sense and antisense transcripts of Ube3a. Hum Mol Genet 2003; 12:837-47; PMID:12668607; http://dx.doi.org/10.1093/hmg/ddg106.
67. Kishino T, Lalande M, Wagstaff J. UBE3A/E6-AP mutations cause Angelman syndrome. Nat Genet 1997; 15:70-3; PMID:8988171; http://dx.doi.org/10.1038/ ng0197-70.
68. Matsuura T, Sutcliffe JS, Fang P, Galjaard RJ, Jiang YH, Benton CS, et al. De novo truncating mutations in E6-AP ubiquitin-protein ligase gene (UBE3A) in Angelman syndrome. Nat Genet 1997; 15:74-7; PMID:8988172; http://dx.doi.org/10.1038/ng0197-74.
69. Huang HS, Allen JA, Mabb AM, King IF, Miriyala J, Taylor-Blake B, et al. Topoisomerase inhibitors unsilence the dormant allele of Ube3a in neurons. Nature 2011; 481:185-9; PMID:22190039; http://dx.doi.org/10.1038/nature10726.
70. Modarresi F, Faghihi MA, Patel NS, Sahagan BG, Wahlestedt C, Lopez-Toledano MA. Knockdown of BACE1-AS Nonprotein-Coding Transcript Modulates Beta-Amyloid-Related Hippocampal Neurogenesis. Int J Alzheimers Dis 2011; 2011:929042; PMID:21785702.
71. Engström PG, Suzuki H, Ninomiya N, Akalin A, Sessa L, Lavorgna G, et al. Complex Loci in human and mouse genomes. PLoS Genet 2006; 2:47; PMID:16683030; http://dx.doi.org/10.1371/journal.pgen.0020047.
72. Vincent JB, Petek E, Thevarkunnel S, Kolozsvari D, Cheung J, Patel M, et al. The RAY1/ST7 tumor-suppressor locus on chromosome 7q31 represents a complex multi-transcript system. Genomics 2002; 80:283-94; PMID:12213198; http://dx.doi.org/10.1006/geno.2002.6835.
73. Millar JK, Wilson-Annan JC, Anderson S, Christie S, Taylor MS, Semple CA, et al. Disruption of two novel genes by a translocation co-segregating with schizophrenia. Hum Mol Genet 2000; 9:1415-23; PMID:10814723; http://dx.doi.org/10.1093/hmg/9.9.1415.
74. Blackwood DH, Fordyce A, Walker MT, St. Clair DM, Porteous DJ, Muir WJ. Schizophrenia and affective disorders - cosegregation with a translocation at chromosome 1q42 that directly disrupts brain-expressed genes: clinical and P300 findings in a family. Am J Hum Genet 2001; 69:428-33; PMID:11443544; http://dx.doi.org/10.1086/321969.
75. Sokolov BP, Polesskaya OO, Uhl GR. Mouse brain gene expression changes after acute and chronic amphetamine. J Neurochem 2003; 84:244-52; PMID:12558987; http://dx.doi.org/10.1046/j.1471-4159.2003.01523.x.
76. Bond AM, Vangompel MJ, Sametsky EA, Clark MF, Savage JC, Disterhoft JF, et al. Balanced gene regulation by an embryonic brain ncRNA is critical for adult hippocampal GABA circuitry. Nat Neurosci 2009; 12:1020-7; PMID:19620975; http://dx.doi.org/10.1038/nn.2371.
77. Di Cristo G, Pizzorusso T, Cancedda L, Sernagor E. GABAergic circuit development and its implication for CNS disorders. Neural Plast 2011; 2011:623705; PMID:22013542; http://dx.doi.org/10.1155/2011/623705.
78. Huarte M, Guttman M, Feldser D, Garber M, Koziol MJ, Kenzelmann-Broz D, et al. A large intergenic noncoding RNA induced by p53 mediates global gene repression in the p53 response. Cell 2010; 142:409-19; PMID:20673990; http://dx.doi.org/10.1016/j.cell.2010.06.040.
79. Hung T, Wang Y, Lin MF, Koegel AK, Kotake Y, Grant GD, et al. Extensive and coordinated transcription of noncoding RNAs within cell cycle promoters. Nat Genet 2011; 43:621-9; PMID:21642992; http://dx.doi.org/10.1038/ng.848.
80. Abrajano JJ, Qureshi IA, Gokhan S, Zheng D, Bergman A, Mehler MF. Differential deployment of REST and CoREST promotes glial subtype specification and oligodendrocyte lineage maturation. PLoS One 2009; 4:7665; PMID:19888342; http://dx.doi.org/10.1371/journal.pone.0007665.
81. Tsai MC, Manor O, Wan Y, Mosammaparast N, Wang JK, Lan F, et al. Long noncoding RNA as modular scaffold of histone modification complexes. Science 2010; 329:689-93; PMID:20616235; http://dx.doi.org/10.1126/science.1192002.
82. Majumder S. REST in good times and bad: roles in tumor suppressor and oncogenic activities. Cell Cycle 2006; 5:1929-35; PMID:16929174; http://dx.doi.org/10.4161/cc.5.17.2982.
83. Lawinger P, Venugopal R, Guo ZS, Immaneni A, Sengupta D, Lu W, et al. The neuronal repressor REST/NRSF is an essential regulator in medulloblastoma cells. Nat Med 2000; 6:826-31; PMID:10888935; http://dx.doi.org/10.1038/77565.
84. Coulson JM. Transcriptional regulation: cancer, neurons and the REST. Curr Biol 2005; 15:665-8; PMID:16139198; http://dx.doi.org/10.1016/j.cub.2005. 08.032.
85. Ku M, Koche RP, Rheinbay E, Mendenhall EM, Endoh M, Mikkelsen TS, et al. Genomewide analysis of PRC1 and PRC2 occupancy identifies two classes of bivalent domains. PLoS Genet 2008; 4:1000242; PMID:18974828; http://dx.doi.org/10.1371/journal.pgen.1000242.
86. Zhao J, Sun BK, Erwin JA, Song JJ, Lee JT. Polycomb proteins targeted by a short repeat RNA to the mouse X chromosome. Science 2008; 322:750-6; PMID:18974356; http://dx.doi.org/10.1126/science.1163045.
87. Kotake Y, Nakagawa T, Kitagawa K, Suzuki S, Liu N, Kitagawa M, et al. Long non-coding RNA ANRIL is required for the PRC2 recruitment to and silencing of p15(INK4B) tumor suppressor gene. Oncogene 2011; 30:1956-62; PMID:21151178; http://dx.doi.org/10.1038/onc.2010.568.
88. Gupta RA, Shah N, Wang KC, Kim J, Horlings HM, Wong DJ, et al. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature 2010; 464:1071-6; PMID:20393566; http://dx.doi.org/10.1038/nature08975.
89. Ernst T, Chase AJ, Score J, Hidalgo-Curtis CE, Bryant C, Jones AV, et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet 2010; 42:722-6; PMID:20601953; http://dx.doi.org/10.1038/ ng.621.
90. Chase A, Cross NC. Aberrations of EZH2 in cancer. Clin Cancer Res 2011; 17:2613-8; PMID:21367748; http://dx.doi.org/10.1158/1078-0432.CCR-10-2156.
91. Orzan F, Pellegatta S, Poliani PL, Pisati F, Caldera V, Menghi F, et al. Enhancer of Zeste 2 (EZH2) is upregulated in malignant gliomas and in glioma stem-like cells. Neuropathol Appl Neurobiol 2011; 37:381-94; PMID:20946108; http://dx.doi.org/10.1111/j.1365-2990.2010.01132.x.
92. Zhang X, Zhou Y, Mehta KR, Danila DC, Scolavino S, Johnson SR, et al. A pituitary-derived MEG3 isoform functions as a growth suppressor in tumor cells. J Clin Endocrinol Metab 2003; 88:5119-26; PMID:14602737; http://dx.doi.org/10. 1210/jc.2003-030222.
93. Kinzler KW, Bigner SH, Bigner DD, Trent JM, Law ML, O'Brien SJ, et al. Identification of an amplified, highly expressed gene in a human glioma. Science 1987; 236:70-3; PMID:3563490; http://dx.doi.org/10.1126/science.3563490.
94. Berteaux N, Aptel N, Cathala G, Genton C, Coll J, Daccache A, et al. A novel H19 antisense RNA overexpressed in breast cancer contributes to paternal IGF2 expression. Mol Cell Biol 2008; 28:6731-45; PMID:18794369; http://dx.doi.org/10.1128/MCB.02103-07.
95. Zamecnik PC, Stephenson ML. Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc Natl Acad Sci USA 1978; 75:280-4; PMID:75545; http://dx.doi.org/10.1073/pnas.75.1.280.
96. Bogdahn U, Hau P, Stockhammer G, Venkataramana NK, Mahapatra AK, Suri A, et al.; Trabedersen Glioma Study Group. Targeted therapy for high-grade glioma with the TGFβ2 inhibitor trabedersen: results of a randomized and controlled phase IIb study. Neuro Oncol 2011; 13:132-42; PMID:20980335; http://dx.doi.org/10.1093/neuonc/noq142.
97. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001; 411:494-8; PMID:11373684; http://dx.doi.org/10.1038/ 35078107.
98. Modarresi F, Faghihi MA, Lopez-Toledano MA, Fatemi RP, Magistri M, Brothers SP, et al. Inhibition of natural antisense transcripts in vivo results in gene-specific transcriptional upregulation. Nat Biotechnol 2012; In press; PMID:22446693; http://dx.doi.org/10.1038/nbt.2158.
99. Henry SP, Novotny W, Leeds J, Auletta C, Kornbrust DJ. Inhibition of coagulation by a phosphorothioate oligonucleotide. Antisense Nucleic Acid Drug Dev 1997; 7:503-10; PMID:9361909; http://dx.doi.org/10.1089/oli.1.1997.7.503.
100. Krieg AM, Yi AK, Matson S, Waldschmidt TJ, Bishop GA, Teasdale R, et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 1995; 374:546-9; PMID:7700380; http://dx.doi.org/10.1038/374546a0.
101. Liang H, Nishioka Y, Reich CF, Pisetsky DS, Lipsky PE. Activation of human B cells by phosphorothioate-oligodeoxynucleotides. J Clin Invest 1996; 98:1119-29; PMID:8787674; http://dx.doi.org/10.1172/JCI118894.
102. Prasad V, Hashim S, Mukhopadhyay A, Basu SK, Roy RP. Oligonucleotides tethered to a short polyguanylic acid stretch are targeted to macrophages: enhanced antiviral activity of a vesicular stomatitis virus-specific antisense oligonucleotide. Antimicrob Agents Chemother 1999; 43:2689-96; PMID:10543748.
103. Agrawal S, Zhao Q, Jiang Z, Oliver C, Giles H, Heath J, et al. Toxicologic effects of an oligodeoxynucleotide-phosphorothioate and its analogs following intravenous administration in rats. Antisense Nucleic Acid Drug Dev 1997; 7:575-84; PMID:9450915; http://dx.doi.org/10.1089/oli.1.1997.7.575.
104. Wahlestedt C, Golanov E, Yamamoto S, Yee F, Ericson H, Yoo H, et al. Antisense oligodeoxynucleotides to NMDA-R1 receptor channel protect cortical neurons from excitotoxicity and reduce focal ischaemic infarctions. Nature 1993; 363:260-3; PMID:8487863; http://dx.doi.org/10.1038/363260a0.
105. Wahlestedt C, Pich EM, Koob GF, Yee F, Heilig M. Modulation of anxiety and neuropeptide Y-Y1 receptors by antisense oligodeoxynucleotides. Science 1993; 259:528-31; PMID:8380941; http://dx.doi.org/10.1126/science.8380941.
106. Chauhan NB, Siegel GJ. Antisense inhibition at the beta-secretase-site of beta-amyloid precursor protein reduces cerebral amyloid and acetyl cholinesterase activity in Tg2576. Neuroscience 2007; 146:143-51; PMID:17303345; http://dx.doi.org/10.1016/j.neuroscience.2007.01.008.
107. Luo MC, Zhang DQ, Ma SW, Huang YY, Shuster SJ, Porreca F, et al. An efficient intrathecal delivery of small interfering RNA to the spinal cord and peripheral neurons. Mol Pain 2005; 1:29; PMID:16191203; http://dx.doi.org/10. 1186/1744-8069-1-29.
108. Passini MA, Bu J, Richards AM, Kinnecom C, Sardi SP, Stanek LM, et al. Antisense oligonucleotides delivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy. SciTransl Med 2011; 3:72; PMID:21368223; http://dx.doi.org/10.1126/scitranslmed.3001777.
109. Smith RA, Miller TM, Yamanaka K, Monia BP, Condon TP, Hung G, et al. Antisense oligonucleotide therapy for neurodegenerative disease. J Clin Invest 2006; 116:2290-6; PMID:16878173; http://dx.doi.org/10.1172/JCI25424.
110. Standifer KM, Chien CC, Wahlestedt C, Brown GP, Pasternak GW. Selective loss of delta opioid analgesia and binding by antisense oligodeoxynucleotides to a delta opioid receptor. Neuron 1994; 12:805-10; PMID:8161452; http://dx.doi.org/10.1016/0896-6273(94)90333-6.
111. Thakker DR, Natt F, Hüsken D, Maier R, Müller M, van der Putten H, et al. Neurochemical and behavioral consequences of widespread gene knockdown in the adult mouse brain by using nonviral RNA interference. Proc Natl Acad Sci USA 2004; 101:17270-5; PMID:15569935; http://dx.doi.org/10.1073/pnas. 0406214101.
112. Hasbi A, Fan T, Alijaniaram M, Nguyen T, Perreault ML, O'Dowd BF, et al. Calcium signaling cascade links dopamine D1-D2 receptor heteromer to striatal BDNF production and neuronal growth. Proc Natl Acad Sci USA 2009; 106:21377-82; PMID:19948956; http://dx.doi.org/10.1073/pnas.0903676106.
113. Choi DC, Maguschak KA, Ye K, Jang SW, Myers KM, Ressler KJ. Prelimbic cortical BDNF is required for memory of learned fear but not extinction or innate fear. Proc Natl Acad Sci USA 2010; 107:2675-80; PMID:20133801; http://dx.doi.org/10.1073/pnas.0909359107.
114. Antal A, Chaieb L, Moliadze V, Monte-Silva K, Poreisz C, Thirugnanasambandam N, et al. Brain-derived neurotrophic factor (BDNF) gene polymorphisms shape cortical plasticity in humans. Brain Stimul 2010; 3:230-7; PMID:20965453; http://dx.doi.org/10.1016/j.brs.2009.12.003.
115. Massa SM, Yang T, Xie Y, Shi J, Bilgen M, Joyce JN, et al. Small molecule BDNF mimetics activate TrkB signaling and prevent neuronal degeneration in rodents. J Clin Invest 2010; 120:1774-85; PMID:20407211; http://dx.doi.org/10. 1172/JCI41356.
116. Laske C, StellosK, Hoffmann N, Stransky E, Straten G, Eschweiler GW, et al. Higher BDNF serum levels predict slower cognitive decline in Alzheimer's disease patients. Int J Neuropsychopharmacol 2011; 14:399-404; PMID:20860877; http://dx.doi.org/10.1017/S1461145710001008.
117. Dell'Osso L, Del Debbio A, Veltri A, Bianchi C, Roncaglia I, Carlini M, et al. Associations between brain-derived neurotrophic factor plasma levels and severity of the illness, recurrence and symptoms in depressed patients. Neuropsychobiology 2010; 62:207-12; PMID:20714169; http://dx.doi.org/10.1159/ 000319946.
118. Phillips HS, Hains JM, Armanini M, Laramee GR, Johnson SA, Winslow JW. BDNF mRNA is decreased in the hippocampus of individuals with Alzheimer's disease. Neuron 1991; 7:695-702; PMID:1742020; http://dx.doi.org/10.1016/0896- 6273(91)90273-3.
119. Nagahara AH, Merrill DA, Coppola G, Tsukada S, Schroeder BE, Shaked GM, et al. Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease. Nat Med 2009; 15:331-7; PMID:19198615; http://dx.doi.org/10.1038/nm.1912.
120. Dash AK, Cudworth GC, 2nd. Therapeutic applications of implantable drug delivery systems. J Pharmacol Toxicol Methods 1998; 40:1-12; PMID:9920528; http://dx.doi.org/10.1016/S1056-8719(98)00027-6.
121. Hua Y, Sahashi K, Hung G, Rigo F, Passini MA, Bennett CF, et al. Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model. Genes Dev 2010; 24:1634-44; PMID:20624852; http://dx.doi.org/ 10.1101/gad.1941310.
122. Hashizume R, Ozawa T, Gryaznov SM, Bollen AW, Lamborn KR, Frey WH, 2nd, et al. New therapeutic approach for brain tumors: Intranasal delivery of telomerase inhibitor GRN163. Neuro Oncol 2008; 10:112-20; PMID:18287341; http://dx.doi.org/10.1215/15228517-2007-052.
123. Michalon A, Sidorov M, Ballard TM, Ozmen L, Spooren W, Wettstein JG, et al. Chronic Pharmacological mGlu5 Inhibition Corrects Fragile X in Adult Mice. Neuron 2012; 74:49-56; PMID:22500629.
124. Waehler R, Russell SJ, Curiel DT. Engineering targeted viral vectors for gene therapy. Nat Rev Genet 2007; 8:573-87; PMID:17607305; http://dx.doi.org/10. 1038/nrg2141.
125. Daemen T, de Mare A, Bungener L, de Jonge J, Huckriede A, Wilschut J. Virosomes for antigen and DNA delivery. Adv Drug Deliv Rev 2005; 57:451-63; http://dx.doi.org/10.1016/j.addr.2004.09.005; PMID:15560951.
126. Ploegh HL. Viral strategies of immune evasion. Science 1998; 280:248-53; PMID:9535648; http://dx.doi.org/10.1126/science.280.5361.248.
127. Jiang Z, Zhao P, Zhou Z, Liu J, Qin L, Wang H. Using attenuated Salmonella typhi as tumor targeting vector for MDR1 siRNA delivery. Cancer Biol Ther 2007; 6:555-60; PMID:17374987; http://dx.doi.org/10.4161/cbt.6.4.3850.
128. Zhang L, Ambulos N, Mixson AJ. DNA delivery to cells in culture using peptides. Methods Mol Biol 2004; 245:33-52; PMID:14707368.
129. Witte A, Wanner G, Sulzner M, Lubitz W. Dynamics of PhiX174 protein E-mediated lysis of Escherichia coli. Arch Microbiol 1992; 157:381-8; PMID:1534215; http://dx.doi.org/10.1007/BF00248685.
130. Kudela P, Paukner S, Mayr UB, Cholujova D, Schwarczova Z, Sedlak J, et al. Bacterial ghosts as novel efficient targeting vehicles for DNA delivery to the human monocyte-derived dendritic cells. J Immunother 2005; 28:136-43; PMID:15725957; http://dx.doi.org/10.1097/01.cji.0000154246.89630.6f.
131. Paukner S, Kohl G, Lubitz W. Bacterial ghosts as novel advanced drug delivery systems: antiproliferative activity of loaded doxorubicin in human Caco-2 cells. J Control Release 2004; 94:63-74; PMID:14684272; http://dx.doi.org/10.1016/j.jconrel.2003.09.010.
132. Paukner S, Kudela P, Kohl G, Schlapp T, Friedrichs S, Lubitz W. DNA-loaded bacterial ghosts efficiently mediate reporter gene transfer and expression in macrophages. Mol Ther 2005; 11:215-23; PMID:15668133; http://dx.doi.org/10.1016/j.ymthe.2004.09.024.
133. Lubitz P, Mayr UB, Lubitz W. Applications of bacterial ghosts in biomedicine. Adv Exp Med Biol 2009; 655:159-70; PMID:20047041; http://dx.doi.org/10.1007/978-1-4419-1132-2-12.
134. Burke B, Tang N, Corke KP, Tazzyman D, Ameri K, Wells M, et al. Expression of HIF-1alpha by human macrophages: implications for the use of macrophages in hypoxia-regulated cancer gene therapy. J Pathol 2002; 196:204-12; PMID:11793372; http://dx.doi.org/10.1002/path.1029.
135. Burke B, Sumner S, Maitland N, Lewis CE. Macrophages in gene therapy: cellular delivery vehicles and in vivo targets. J Leukoc Biol 2002; 72:417-28; PMID:12223508.
136. Dou H, Grotepas CB, McMillan JM, Destache CJ, Chaubal M, Werling J, et al. Macrophage delivery of nanoformulated antiretroviral drug to the brain in a murine model of neuroAIDS. J Immunol 2009; 183:661-9; PMID:19535632; http://dx.doi.org/10.4049/jimmunol.0900274.